Marfan Syndrome is a rare genetic disorder affecting connective tissue, leading to heart, eye, bone, and joint issues.

Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for ...

Celebrate the contributions of Noorin Jamal, a nursing hero who enhances clinical care through her groundbreaking work in ...

IRVINE, CA / ACCESS Newswire / May 1, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, ...

Severe tricuspid valve regurgitation is a serious heart condition. The development of tricuspid valve implants is still in ...

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve ...

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis ...

The agency’s decision for the balloon-expandable Sapien 3 platform is based on groundbreaking results from EARLY TAVR.

Edwards Lifesciences announced the FDA approved its transcatheter aortic valve replacement platform for treatment of severe ...

The mouth is often described as a window to overall health - and for good reason. A growing body of research reveals a significant link between poor ...

Edwards’ SAPIEN 3 platform becomes the first TAVR system approved by the FDA for asymptomatic severe aortic stenosis patients ...

By Sunil Inamdar, Vice President of Technical Development, Polyzen Specialized, custom-shaped low-pressure balloons are ...